ATNM

1.88

6.82% 0.12

Handel nachbörslich: 1.83 -0.05 -2.66%

Actinium Pharmaceuticals Inc (ATNM)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.76

Offen:

$1.76

24-Stunden-Volumen:

224.27K

Relative Volume:

0.29

Marktkapitalisierung:

$58.57M

Einnahmen:

$1.05M

Nettoeinkommen (Verlust:

$-48.82M

KGV:

-1.033

EPS:

-1.82

Netto-Cashflow:

$-47.49M

1W Leistung:

+0.00%

1M Leistung:

+5.03%

6M Leistung:

-79.02%

1J Leistung:

-60.50%

1-Tages-Spanne:

$1.76

$1.88

1-Wochen-Bereich:

$1.69

$1.89

52-Wochen-Spanne:

$1.33

$10.24

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Firmenname

Actinium Pharmaceuticals Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

646-767-3870

Adresse

275 Madison Avenue, 7th Floor, New York, NY

Mitarbeiter

Twitter

@actiniumpharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

ATNM's Discussions on Twitter

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-02-21	Herabstufung	William Blair	Outperform → Mkt Perform
2022-09-08	Eingeleitet	Cantor Fitzgerald	Overweight
2022-08-25	Eingeleitet	B. Riley Securities	Buy
2020-11-05	Eingeleitet	Alliance Global Partners	Buy
2017-12-06	Eingeleitet	B. Riley FBR, Inc.	Buy
2017-10-23	Fortgesetzt	ROTH Capital	Buy
2017-09-14	Eingeleitet	Maxim Group	Buy
2016-08-25	Eingeleitet	ROTH Capital	Buy
2016-02-29	Eingeleitet	H.C. Wainwright	Buy
2015-10-15	Eingeleitet	FBR Capital	Outperform
2014-10-01	Eingeleitet	MLV & Co	Buy
2014-07-22	Eingeleitet	Canaccord Genuity	Buy

Alle ansehen

Actinium Pharmaceuticals Inc Aktie (ATNM) Neueste Nachrichten

02:11 AM

Vanguard Group's Recent Acquisition in Actinium Pharmaceuticals - GuruFocus.com

02:11 AM

Nov 04, 2024

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PR Newswire

Nov 04, 2024

Nov 03, 2024

Adlai Nortye (NASDAQ:ANL) & Actinium Pharmaceuticals (NYSE:ATNM) Financial Comparison - Defense World

Nov 03, 2024

Nov 02, 2024

Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - MSN

Nov 02, 2024

Oct 21, 2024

The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World

Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Oct 21, 2024

Oct 18, 2024

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Yahoo Finance

Oct 18, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Oct 18, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 18, 2024

Oct 16, 2024

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - The Manila Times

Oct 16, 2024

Oct 15, 2024

Hodgkin's Lymphoma Market Size, Share, Growth Insights - openPR

Oct 15, 2024

Oct 14, 2024

Renaissance Technologies LLC Invests $142,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World

Oct 14, 2024

Oct 09, 2024

Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com - Defense World

Oct 09, 2024

Oct 01, 2024

Comparing Actinium Pharmaceuticals (ATNM) and Its Competitors - Defense World

Oct 01, 2024

Sep 30, 2024

Radiopharmaceuticals Market Report, Size, Share, Growth, Trends, Industry Analysis, Forecast to 2033 - WhaTech

Sep 30, 2024

S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge - MSN

Sep 30, 2024

Sep 27, 2024

Wall Street SWOT: Actinium stock rides wave of targeted therapy innovation - Investing.com

Sep 27, 2024

Sep 25, 2024

Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

Sep 25, 2024

Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World

Sep 25, 2024

Sep 24, 2024

Bank of New York Mellon Corp Increases Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World

Sep 24, 2024

Sep 23, 2024

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - Clinical Trials Arena

Sep 23, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 23, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Sep 23, 2024

Sep 22, 2024

Stocks of the Hour: Amplia Therapeutics, Wellard, Anax Metals - ShareCafe

Sep 22, 2024

Sep 21, 2024

Before Buying Anterix Inc (NASDAQ: ATEX) Stock, Read This First - Stocks Register

Sep 21, 2024

Sep 20, 2024

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan

Sep 20, 2024

Sep 19, 2024

Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM

Sep 19, 2024

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

Sep 19, 2024

Sep 18, 2024

Stock Analysts’ Downgrades for September 18th (ATNM, BHR, CALX, FITB, MEDP, MMSI, MOH, MTRX, NPK, PRMW) - Defense World

Sep 18, 2024

Sep 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc.ATNM - PR Newswire

Sep 17, 2024

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific - Clinical Trials Arena

Sep 17, 2024

Sep 09, 2024

Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.

Sep 09, 2024

Sep 06, 2024

ATNM: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 06, 2024